Search results for "chemotherapy"

showing 10 items of 1871 documents

Endoscopic management of gastric outlet obstruction disease

2019

Gastric outlet obstruction (GOO) is a clinical syndrome characterized by a variety of symptoms. It may be caused by motor disorders and by benign or malignant mechanical disease. Endoscopic management of benign disease is mainly based on balloon dilation, augmented by the use of covered self-expanding metal stents (SEMS) in refractory disease. Endoscopic ultrasound-guided gastroenterostomy (EUS-GE) is increasingly used as an alternative method, although more studies with longer follow up are needed before it can be considered as a recommended therapy. Surgery remains the last resort. Endoscopic management of malignant GOO is based on SEMS placement as an alternative to palliative surgery, b…

medicine.medical_specialtymedicine.medical_treatmentReview ArticleDisease03 medical and health sciences0302 clinical medicinemedicineendoscopic ultrasound-guided gastroenterostomyChemotherapybusiness.industryBile ductGastroenterologyStentGastric outlet obstructionGastroenterostomymedicine.diseaseSurgerymetal stentsmedicine.anatomical_structure030220 oncology & carcinogenesisConcomitantGastric outlet obstruction diseaseBalloon dilation030211 gastroenterology & hepatologyendoscopic balloon dilationbusinessAnnals of Gastroenterology
researchProduct

Retrospective clinical evaluation of root canal treatment with or without photodynamic therapy for necrotic teeth and teeth subjected to retreatment.

2021

PURPOSE To compare the effect of photodynamic therapy (PDT) as a procedure to complement root canal treatment (RCT), for both primary treatment and retreatment. METHODS This was a retrospective study based on analysis of clinical records. A total of 214 teeth that had undergone RCT on either a primary or retreatment basis, with or without complementary PDT, were evaluated. For 118 teeth that met the previously established inclusion criteria, the time until healing was evaluated. Complementarily, the need for application of calcium hydroxide (CaHy) between visits and the number of visits necessary for completing the treatment were assessed. Data were analyzed using the Mann-Whitney and χ2 te…

medicine.medical_specialtymedicine.medical_treatmentRoot canalPhotodynamic therapylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawStatistical significancemedicineGeneral DentistryRetrospective Studiesbusiness.industryRetrospective cohort study030206 dentistrySurgeryRoot Canal TherapyPeriapical lesionmedicine.anatomical_structureTreatment OutcomePhotochemotherapyRetreatmentDental Pulp CavitybusinessClinical evaluationClinical record030217 neurology & neurosurgeryJournal of oral science
researchProduct

Corneal opacity and copper levels of the Lewis syndrome after systemic chemotherapy

2020

Abstract Purpose To report a female patient of biclonal Lewis syndrome which consists of a trias: biclonal gammopathy of undetermined significance, paraproteinemic keratopathy in form of a brownish discoid opacification at the level of Descemet's membrane and hypercupremia. After several years there was a conversion to multiple myeloma. Systemic chemotherapy led to a complete remission of multiple myeloma and to a normalization of the copper level in the blood that lasted five years. The corneal opacification remained unchanged. Observations A currently 66-year-old woman suffered from biclonal Lewis syndrome. On both eyes there is a central discoid yellow-brownish discoloration in the Pre-D…

medicine.medical_specialtymedicine.medical_treatmentUnchanged corneal opacity after chemotherapyGastroenterology03 medical and health sciences0302 clinical medicinelcsh:OphthalmologyChemotherapy-induced normal level of copper in serumInternal medicineMedicineAffinity of IgG to copper in Lewis syndromeCopper levelsProgressive anemiaMultiple myelomaLewis syndromeHypercupremiaChemotherapyBiclonal gammopathybusiness.industrySystemic chemotherapyHypercupremiaCorneal opacitymedicine.diseaseOphthalmologylcsh:RE1-994030221 ophthalmology & optometrybusinessDiscoid brownish opacification of Descemet membrane030217 neurology & neurosurgeryAmerican Journal of Ophthalmology Case Reports
researchProduct

Osteoblastic osteogenic sarcoma in a 13-month-old girl.

1994

Summary Osteosarcoma is exceptional in early periods of life. Therefore osteosarcomas involvingthe bones of the hand are extremely rare. We present a case of an osteogenic sarcoma involving the second metacarpal bone of a 13-month-old girl who has been remaining free of disease, after treatment — radial amputation and chemotherapy pre- and post-operative-, for a period of 10 years in the follow-up.

medicine.medical_specialtymedicine.medical_treatmentmedia_common.quotation_subjectSecond metacarpal boneAmputation SurgicalPathology and Forensic MedicineFingersAntineoplastic Combined Chemotherapy Protocolsmedicinemedicine.boneHumansGirlmedia_commonChemotherapyOsteosarcomabusiness.industryInfantCell Biologymedicine.diseaseCombined Modality TherapySurgeryRadiographyAmputationOsteosarcomaFemaleSarcomaMetacarpusbusinessAfter treatmentFollow-Up StudiesPathology, research and practice
researchProduct

Intravesical chemotherapy for intermediate risk non-muscle invasive bladder cancer recurring after a first cycle of intravesical adjuvant therapy

2015

Context: The therapeutic strategy in intermediate risk (IR) non-muscle invasive bladder cancer (NMIBC) recurring after intravesical therapy (IT) is not well defined. Most patients are usually retreated by Bacillus Calmette-Guerin (BCG). Aims: To evaluate the efficacy of intravesical chemotherapy (ICH) given at recurrence after the first cycle of ICH in IR-NMIBC recurring 6 months or later. Settings and Design: Retrospective analysis of the efficacy of ICH given after previous IT. Materials and Methods: The clinical files of IR-NMIBC patients recurring later than 6 months after transurethral resection (TUR) and IT and retreated by IT were reviewed. The patients should be at intermediate risk…

medicine.medical_specialtyrecurrenceUrologyContext (language use)intermediate risklcsh:RC870-923Settore MED/24 - UrologiaCytologyintravesical chemotherapyAdjuvant therapyMedicinecardiovascular diseasesBacillus Calmette-GuerinBladder cancermedicine.diagnostic_testbusiness.industryProportional hazards modelCystoscopylcsh:Diseases of the genitourinary system. Urologymedicine.diseaseSurgerynervous system diseasesBacillus Calmette-Guerin intermediate risk intravesical chemotherapy non muscle invasive bladder cancer recurrenceMann–Whitney U testnon muscle invasive bladder cancerOriginal ArticlebusinessIntravesical chemotherapyUrology Annals
researchProduct

Laparoscopy versus open adrenalectomy in patients with solid tumor metastases: results of a multicenter European study

2020

Background: The outcome of adrenalectomy carried out by laparoscopy or open surgery for solid tumor metastases was assessed. Methods: A total of 317 patients with histologically confirmed adrenal metastatic disease collected from 30 centres in Europe underwent adrenalectomy by laparoscopy (n=146) or open laparotomy (n=171). Differences between laparoscopic and open adrenalectomy were assessed by a single Cox analysis for both procedures. Results: The median overall survival was 24.0 [95% confidence interval (CI): 21.4-26.6] months for open adrenalectomy and 45.0 (95% CI: 22.6-67.4) for laparoscopic adrenalectomy (P=0.008). Survival rates were 68%, 49%, 35% and 29% at 1, 2, 3 and 5 years for…

medicine.medical_specialtyretrospective studymedicine.medical_treatmentUrologysurvivalMetastasis03 medical and health sciences0302 clinical medicineMetàstasiLaparotomymedicineLaparoscopyTumorsChemotherapymedicine.diagnostic_testbusiness.industryAdrenalectomyHazard ratioopen adrenalectomyAdrenalectomyRetrospective cohort studymedicine.diseasePrimary tumorConfidence interval3. Good healthLaparoscòpiaAdrenalectomy; open adrenalectomy; laparoscopic adrenalectomy; survival; retrospective study030220 oncology & carcinogenesisOriginal ArticleLaparoscopy030211 gastroenterology & hepatologySurgerybusinesslaparoscopic adrenalectomyGland Surgery
researchProduct

Salivary gland cancer in Southern Brazil: a prognostic study of 107 cases.

2020

Background Salivary gland cancers (SGC) represent an uncommon group of heterogeneous tumors. We performed a retrospective survey of SGC diagnosed in a reference center for treatment of malignant tumors from the south of Brazil aiming to determine the prognostic value of demographic, clinic and pathologic features. Material and Methods Cases diagnosed as SGC between 2006 and 2016 were retrospectively collected. Medical records were examined to extract demographic, clinic, pathologic and follow-up information. Results One-hundred and seven cases of SGC were identified. The most common SGC were mucoepidermoid carcinoma (MEC) (n = 39) followed by adenoid cystic carcinoma (AdCC) (n = 29). Among …

medicine.medical_specialtysjögren syndromeAdenoid cystic carcinomamedicine.medical_treatmentsalivary glandsPerineural invasionGastroenterologyMucoepidermoid carcinomaInternal medicineOral Cancer and Potentially malignant disordersmedicineHumansIntermediate GradexerostomiaGeneral DentistryUNESCO:CIENCIAS MÉDICASRetrospective StudiesChemotherapySalivary glandbusiness.industryResearchNeck dissectionmedicine.diseasePrognosisSalivary Gland Neoplasmsmedicine.anatomical_structureOtorhinolaryngologySalivary gland cancerSurgeryNeoplasm Recurrence LocalbusinessBrazilMedicina oral, patologia oral y cirugia bucal
researchProduct

Novel Combination of Sorafenib and Celecoxib Provides Synergistic Anti-Proliferative and Pro-Apoptotic Effects in Human Liver Cancer Cells

2013

Molecular targeted therapy has shown promise as a treatment for advanced hepatocellular carcinoma (HCC). Sorafenib, a multikinase inhibitor, recently received FDA approval for the treatment of advanced HCC. However, although sorafenib is well tolerated, concern for its safety has been expressed. Celecoxib (Celebrex®) is a selective cyclooxygenase-2 (COX-2) inhibitor which exhibits antitumor effects in human HCC cells. The present study examined the interaction between celecoxib and sorafenib in two human liver tumor cell lines HepG2 and Huh7. Our data showed that each inhibitor alone reduced cell growth and the combination of celecoxib with sorafenib synergistically inhibited cell growth an…

medicine.medical_treatmentCancer TreatmentGene ExpressionApoptosisPharmacologyBiochemistryTargeted therapy0302 clinical medicineMolecular Cell Biology0303 health sciencesSulfonamidesMultidisciplinaryReverse Transcriptase Polymerase Chain ReactionQLiver NeoplasmsRDrug SynergismGenomicsSorafenib3. Good healthGene Expression Regulation NeoplasticOncology030220 oncology & carcinogenesisMedicineLiver cancermedicine.drugResearch ArticleBiotechnologySignal TransductionSorafenibNiacinamideProgrammed cell deathCarcinoma HepatocellularScienceBlotting WesternBiologyMolecular Genetics03 medical and health sciencesCell Line TumorGastrointestinal TumorsmedicineIn Situ Nick-End LabelingHumansneoplasmsBiology030304 developmental biologyCell ProliferationDNA PrimersHuman liver cancer Apoptosis Sorafenib Celecoxib anti-proliferative effectsCell growthGene Expression ProfilingPhenylurea CompoundsComputational BiologyCancers and NeoplasmsHepatocellular CarcinomaChemotherapy and Drug Treatmentmedicine.diseaseMicroarray Analysisdigestive system diseasesGene expression profilingApoptosisCell cultureCelecoxibPyrazolesGenome Expression AnalysisPLoS ONE
researchProduct

Tubular carcinoma of the breast: Outcome and loco-regional recurrence in 307 patients

2005

Abstract Purpose The aim of this study is to describe the University of Florence experience in evaluating clinical, pathologic and treatment factors as they are related to the outcome and loco-regional recurrence in patients with tubular breast carcinoma. Material and methods Three hundred and seven patients (median age 56.4 years, range 26–91 years) with histological verified tubular carcinoma of the breast were consecutively treated at University of Florence from 1976 to 2001. All patients were followed for a median of 8.4 years (range 3 months to 20 years). Thirty-seven women underwent mastectomy and 270 underwent breast conserving surgery. Positive axillary nodes were found in 15% of pa…

medicine.medical_treatmentDiseaseSegmentalMastectomy SegmentalBreast cancerDuctalBreast-conserving surgery80 and overBreastAdjuvantMastectomyAged 80 and overCarcinoma Ductal BreastTubular carcinomaGeneral MedicineMiddle AgedCombined Modality TherapyTreatment OutcomeBreast cancer; Radiotherapy; Tubular carcinoma; Adenocarcinoma; Adult; Aged; Aged 80 and over; Antineoplastic Agents Hormonal; Axilla; Breast Neoplasms; Carcinoma Ductal Breast; Chemotherapy Adjuvant; Combined Modality Therapy; Female; Humans; Lymphatic Metastasis; Mastectomy; Mastectomy Segmental; Middle Aged; Neoplasm Recurrence Local; Proportional Hazards Models; Radiotherapy Adjuvant; Survival Analysis; Tamoxifen; Treatment Outcome; Oncology; SurgeryLocalOncologyChemotherapy AdjuvantLymphatic MetastasisFemaleMastectomymedicine.drugAdultmedicine.medical_specialtyAntineoplastic Agents HormonalAntineoplastic AgentsBreast NeoplasmsAdenocarcinomaBreast cancermedicineChemotherapyHumansAgedProportional Hazards ModelsChemotherapyRadiotherapyHormonalbusiness.industryCarcinomamedicine.diseaseSurvival AnalysisSurgeryRadiation therapyTamoxifenNeoplasm RecurrenceAxillaRadiotherapy AdjuvantSurgeryTubular carcinomaNeoplasm Recurrence LocalbusinessTamoxifen
researchProduct

Evaluation of Flavonoid Derivative and Doxorubicin Effects in Lung Cancer Cells (A549) Using Differential Pulse Voltammetry Method.

2018

Purpose: Electrochemical measurements have prompted the progress as a consequence of their affectability, cost-affectivity and comparatively short examination time. The aim of this study was the fast evaluation of the effect of chemotherapy compounds on the viability of lung cancer cells (A549) via electrochemical methods. Methods: Cyclic voltammetry (CV) was used as a primary method to distinguish between electrochemical behavior of normal and lung cancer cells. Differential pulse voltammetry (DPV) was employed as a complementary analyses method for the impact of doxorubicin (DOX) and Flavonoid modified drug (FMD) (US patent Application number: 62548886) on Lung cancer cells. Results: Only…

medicine.medical_treatmentFlavonoidPharmaceutical SciencePharmacology01 natural sciences0404 agricultural biotechnologyLung neoplasmsElectrochemistrymedicineDoxorubicinGeneral Pharmacology Toxicology and PharmaceuticsLung cancerVoltammetrychemistry.chemical_classificationChemotherapylcsh:RM1-950010401 analytical chemistry04 agricultural and veterinary sciencesmedicine.disease040401 food science0104 chemical scienceslcsh:Therapeutics. PharmacologychemistryDoxorubicinCancer cellVoltammetryDifferential pulse voltammetryCyclic voltammetryResearch Articlemedicine.drugAdvanced pharmaceutical bulletin
researchProduct